Robert Kuo
Family Medicine · Atlanta, GANPI 1801208657
Payments from drug & device makers
Across 249 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$696
- Novo Nordisk$693
- Lilly USA, LLC$574
- Amgen$348
- Viiv Healthcare Company$319
- GSK$269
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,975100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $696 |
| Novo Nordisk | 34 | $693 |
| Lilly USA, LLC | 34 | $574 |
| Amgen | 14 | $348 |
| Viiv Healthcare Company | 13 | $319 |
| GSK | 16 | $269 |
| Pfizer | 14 | $263 |
| Novartis | 10 | $229 |
| AbbVie(2 entities) | 11 | $177 |
| Boehringer Ingelheim | 7 | $175 |
| Exact Sciences | 10 | $159 |
| Astellas Pharma US Inc | 6 | $149 |
| MDD US Operations, LLC | 1 | $114 |
| Abbott | 6 | $108 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Merck | 5 | $75 |
| Ultragenyx Pharmaceutical Inc. | 4 | $73 |
| Cranial Technologies, Inc | 4 | $50 |
| Dexcom, Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $43 |
| Dynavax Technologies Corporation | 2 | $39 |
| Bayer | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Braemar Manufacturing, LLC | 1 | $20 |
| Gilead | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,981 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 124 | $148,516 |
| OzempicSemaglutide | 69 | $94,254 |
| FarxigaDapagliflozin Propanediol | 59 | $59,327 |
| EliquisApixaban | 48 | $52,794 |
| TrulicityDulaglutide | 30 | $47,275 |
| MounjaroTirzepatide | 27 | $29,798 |
| LinzessLinaclotide | 22 | $25,208 |
| RybelsusSemaglutide | 11 | $24,834 |
| JanuviaSitagliptin Phosphate | 18 | $23,477 |
| MyrbetriqMirabegron | 12 | $8,404 |
| Atorvastatin Calcium | 794 | $8,205 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $4,818 |
| Amlodipine Besylate | 745 | $3,788 |
| Ezetimibe | 193 | $3,306 |
| Losartan Potassium | 277 | $2,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $175 | $148,516124 claims |
| Novo NordiskOzempic, Rybelsus | $693 | $119,08880 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $574 | $77,07357 claims |
| AstraZenecaFarxiga | $696 | $59,32759 claims |
| PfizerEliquis | $263 | $52,79448 claims |
| AbbVieLinzess, Synthroid | $177 | $26,31137 claims |
| MerckJanuvia | $75 | $23,47718 claims |
| Astellas Pharma US IncMyrbetriq | $149 | $8,40412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Atlanta
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Nadia CameronAtlanta$2.1M
- Otis PowellAtlanta$608K
- Thinh NguyenAtlanta$427K
- Patricia MarshAtlanta$175K
- Contessa MetcalfeAtlanta$157K
- Michelle EvansAtlanta$127K
- Mark TannerAtlanta$94K
- Ambar KulshreshthaAtlanta$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.